Efficacy News and Research

RSS
Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

New cell-based profiling service from RBC and Promega

New cell-based profiling service from RBC and Promega

Hope for paraplegics in the horizon

Hope for paraplegics in the horizon

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

New TB vaccine effective in half of the population in phase II trials

New TB vaccine effective in half of the population in phase II trials

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

FDA grants Orphan Drug Designation to Myelo001 for treatment of Acute Radiation Syndrome

NeoTract presents new clinical data from studies of UroLift System for patients with BPH

NeoTract presents new clinical data from studies of UroLift System for patients with BPH

Tomocube introduces new holotomography microscope for live cell imaging

Tomocube introduces new holotomography microscope for live cell imaging

Hybrid theranostic complex shows high therapeutic efficacy against tumor cells

Hybrid theranostic complex shows high therapeutic efficacy against tumor cells

Researchers for the first time crash caged populations of malaria vector mosquito

Researchers for the first time crash caged populations of malaria vector mosquito

Genomic ‘islands’ evolved from viruses can be converted into ‘anti-bacterial drones’

Genomic ‘islands’ evolved from viruses can be converted into ‘anti-bacterial drones’

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

Clinical study shows efficacy, safety of novel drug-eluting stent with improved radiographic visibility

Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System

Ancora Heart announces positive data of study evaluating AccuCinch Ventricular Repair System

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.